The FDA granted fast track designation to RAD101, an experimental imaging agent, to improve detection of recurrent brain ...

About BJT-188 BJT-188 is a preclinical, liver-targeted fatty acid synthase (FASN) inhibitor currently under investigation by Bluejay Therapeutics for the treatment of metabolic dysfunction ...

RAD101 is the Company's novel imaging small molecule that targets fatty acid synthase (FASN), a multi-enzyme protein that ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) said on Wednesday that denifanstat met all primary and secondary endpoints in a Phase ...

Sagimet Biosciences Inc. (NASDAQ:SGMT) saw its stock soar 20% after unveiling encouraging Phase 3 trial results for its acne ...

Sagimet Biosciences' FASN inhibitors show promise in acne and metabolic disease. Read my analysis on SGMT stock and see why I ...

Sagimet Biosciences (NASDAQ:SGMT) added ~38% in the premarket on Wednesday after the company said its Chinese licensing ...

Ascletis Pharma’s acne pill has scored a phase 3 win, leading the Chinese biotech to claim the Sagimet Biosciences-sourced ...

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). BJT-188 demonstrated potent FASN inhibition ...